Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research
Posted: 8 June 2016 | | No comments yet
Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
The presentation will be on the results of the first U.S. observational study exploring the impact of biomarkers on treatment response for Orencia and TNF-inhibitors in moderate to severe rheumatoid arthritis (RA).
The study found that patients who tested positive for certain biomarkers of poor prognosis (anti-CCP or RF) were more likely to have a greater response with Orencia treatment than patients testing negative for the biomarkers.
Orencia holds promise for rheumatoid arthritis
The study analysed data from the Corrona, LLC RA registry, the largest RA cohort prospectively followed in North America. The analysis included patients with RA who had been tested for both anti-CCP and RF, and received Orencia – a T cell co-stimulation blocker (n=566) – or another class of RA biologic medicines, TNF-inhibitors (n=1715) over a 12 and a half year period.
“As a leader in the field of immunoscience, Bristol-Myers Squibb is dedicated to the research of disease biomarkers and finding transformative ways that may help reduce the impact of autoimmune diseases like RA,” said Douglas Manion, M.D., Head of Specialty Development, Bristol-Myers Squibb.
“The real-world data from the Corrona RA registry study showed patients who are seropositive for anti-CCP or RF, and particularly those who are double seropositive, were more likely to have incremental improvements in response to Orencia than if they were negative for these biomarkers as compared to those who initiated TNF-inhibitors.”
“These findings and scientific insights underscore our decade-long commitment to ongoing Orencia research.”
The Corrona RA registry is a real-world observational study that has collected data from 662 participating rheumatologists in 168 rheumatology practices across 40 states in the U.S. It currently includes data from more than 40,000 patients with RA.